N 0861

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534879

CAS#: 141696-90-4

Description: N 0861 is an adenosine receptor antagonist.

Chemical Structure

N 0861
CAS# 141696-90-4

Theoretical Analysis

MedKoo Cat#: 534879
Name: N 0861
CAS#: 141696-90-4
Chemical Formula: C13H17N5
Exact Mass: 243.1484
Molecular Weight: 243.314
Elemental Analysis: C, 64.17; H, 7.04; N, 28.78

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: N 0861; N-0861; N0861

IUPAC/Chemical Name: 9H-Purin-6-amine, N-bicyclo(2.2.1)hept-2-yl-9-methyl-, endo-(+-)-


InChi Code: InChI=1S/C13H17N5/c1-18-7-16-11-12(14-6-15-13(11)18)17-10-5-8-2-3-9(10)4-8/h6-10H,2-5H2,1H3,(H,14,15,17)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 243.314 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bertolet BD, Belardinelli L, Franco EA, Nichols WW, Kerensky RA, Hill JA. Selective attenuation by N-0861 (N6-endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptor-mediated effects in humans. Circulation. 1996 May 15;93(10):1871-6. doi: 10.1161/01.cir.93.10.1871. PMID: 8635266.

2: Glover DK, Ruiz M, Sansoy V, Barrett RJ, Beller GA. Effect of N-0861, a selective adenosine A1 receptor antagonist, on pharmacologic stress imaging with adenosine. J Nucl Med. 1995 Feb;36(2):270-5. PMID: 7830130.

3: Shryock JC, Travagli HC, Belardinelli L. Evaluation of N-0861, (+-)-N6-endonorbornan-2-yl-9-methyladenine, as an A1 subtype-selective adenosine receptor antagonist in the guinea pig isolated heart. J Pharmacol Exp Ther. 1992 Mar;260(3):1292-9. PMID: 1545393.

4: Barrett RJ, Droppleman DA, Wright KF. N-0861 selectively antagonizes adenosine A1 receptors in vivo. Eur J Pharmacol. 1992 May 27;216(1):9-16. doi: 10.1016/0014-2999(92)90202-f. PMID: 1526257.

5: Yasuda SU, Nagashima S, Douyon E, Benton RE, Woosley RL, Barbey JT. Adenosine A1-receptor occupancy predicts A1-receptor antagonist effects of N-0861. Clin Pharmacol Ther. 1998 Nov;64(5):536-41. doi: 10.1016/S0009-9236(98)90136-9. PMID: 9834045.

6: Martin PL, Potts AA, Sykes AM, McKenna DG. (+-)-N6-endonorbornan-2-yl-9-methyladenine (N-0861) and its enantiomers: selective antagonists of A1-adenosine receptors in guinea pig isolated atria. J Pharmacol Exp Ther. 1993 Apr;265(1):201-6. PMID: 8474007.

7: Sidi A, Wesley R, Barrett R, Rush W, Belardinelli L. Cardiovascular effects of a non-xanthine-selective antagonist of the A1 adenosine receptor in the anaesthetised pig: pharmacological and therapeutic implications. Cardiovasc Res. 1994 May;28(5):621-8. doi: 10.1093/cvr/28.5.621. PMID: 8025906.

8: Wesley RC Jr, Porzio D, Sadeghi M. Effect of selective A1 adenosine receptor antagonism of postdefibrillation cardiovascular depression: evidence for an antiadrenergic role of endogenous adenosine. Cardiovasc Res. 1993 Jan;27(1):129-33. doi: 10.1093/cvr/27.1.129. PMID: 8458023.

9: Belardinelli L, Shryock JC, Zhang Y, Scammells PJ, Olsson R, Dennis D, Milner P, Pfister J, Baker SP. 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells. J Pharmacol Exp Ther. 1995 Dec;275(3):1167-76. PMID: 8531078.

10: Martin PL, Wysocki RJ Jr, Barrett RJ, May JM, Linden J. Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J Pharmacol Exp Ther. 1996 Feb;276(2):490-9. PMID: 8632314.

11: Shryock JC, Ozeck MJ, Belardinelli L. Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol. 1998 May;53(5):886-93. PMID: 9584215.

12: Martin PL, May JM. Identification and functional characterization of A1 and A2 adenosine receptors in the rat vas deferens: a comparison with A1 receptors in guinea pig left atrium and A2 receptors in guinea pig aorta. J Pharmacol Exp Ther. 1994 Jun;269(3):1228-35. PMID: 8014866.

13: Barrett RJ, Wright KF. A selective adenosine A1 receptor antagonist attenuates renal dysfunction during controlled hypotension with adenosine in rats. Anesth Analg. 1994 Sep;79(3):460-5. doi: 10.1213/00000539-199409000-00010. PMID: 8067549.

14: Fahim M, Mustafa SJ. Evidence for the presence of A(1) adenosine receptors in the aorta of spontaneously hypertensive rats. Br J Pharmacol. 2001 Dec;134(8):1760-6. doi: 10.1038/sj.bjp.0704433. PMID: 11739253; PMCID: PMC1572910.

15: Kodani E, Bolli R, Tang XL, Auchampach JA. Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor. Basic Res Cardiol. 2001 Sep;96(5):487-96. doi: 10.1007/s003950170031. PMID: 11605996.

16: Takano H, Bolli R, Black RG Jr, Kodani E, Tang XL, Yang Z, Bhattacharya S, Auchampach JA. A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res. 2001 Mar 16;88(5):520-8. doi: 10.1161/01.res.88.5.520. PMID: 11249876.

17: Song Y, Thedford S, Lerman BB, Belardinelli L. Adenosine-sensitive afterdepolarizations and triggered activity in guinea pig ventricular myocytes. Circ Res. 1992 Apr;70(4):743-53. doi: 10.1161/01.res.70.4.743. PMID: 1551200.

18: Barrett RJ. Realizing the potential of adenosine-receptor-based therapeutics. Proc West Pharmacol Soc. 1996;39:61-6. PMID: 8895971.

19: Giannella E, Mochmann HC, Levi R. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res. 1997 Sep;81(3):415-22. doi: 10.1161/01.res.81.3.415. PMID: 9285644.

20: Meester BJ, Shankley NP, Welsh NJ, Wood J, Meijler FL, Black JW. Pharmacological classification of adenosine receptors in the sinoatrial and atrioventricular nodes of the guinea-pig. Br J Pharmacol. 1998 Jun;124(4):685-92. doi: 10.1038/sj.bjp.0701891. PMID: 9690860; PMCID: PMC1565446.